Cartesian Therapeutics Inc. - Asset Resilience Ratio
Cartesian Therapeutics Inc. (RNAC) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Cartesian Therapeutics Inc. to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how Cartesian Therapeutics Inc.'s Asset Resilience Ratio has changed over time. See Cartesian Therapeutics Inc. net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Cartesian Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cartesian Therapeutics Inc. market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Cartesian Therapeutics Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Cartesian Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Cartesian Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Cartesian Therapeutics Inc. (2014–2023)
The table below shows the annual Asset Resilience Ratio data for Cartesian Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.45% | $-1.38 Million | $305.05 Million | -81.59pp |
| 2022-12-31 | 81.14% | $134.60 Million | $165.89 Million | +1.05pp |
| 2021-12-31 | 80.09% | $128.06 Million | $159.88 Million | -3.74pp |
| 2020-12-31 | 83.83% | $138.69 Million | $165.44 Million | -6.45pp |
| 2019-12-31 | 90.28% | $89.89 Million | $99.57 Million | +6.20pp |
| 2018-12-31 | 84.09% | $37.40 Million | $44.48 Million | -11.43pp |
| 2017-12-31 | 95.51% | $96.56 Million | $101.10 Million | +1.29pp |
| 2016-12-31 | 94.22% | $84.14 Million | $89.30 Million | +84.59pp |
| 2015-12-31 | 9.63% | $4.12 Million | $42.82 Million | +4.04pp |
| 2014-12-31 | 5.60% | $1.24 Million | $22.23 Million | -- |
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune disease… Read more